Hemato-oncological patients with thrombocytopenia and transfusion dependent
Conditions
Interventions
All patients will be randomized to receive one of three platelet products during one transfusion period:
1. Arm A: Plasma stored platelet concentrates (Plasma-PC)
2. Arm B: PAS III stored platelet concentrates (PAS III-PC)
3. Arm C: Pathogen reduced PAS III stored platelet concentrates (PR-PAS III-PC).
Sponsors
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)
P/a HOVON Data Center
Erasmus MC - Daniel den Hoed
Postbus 5201
3008 AE Rotterdam
Tel: 010 4391568
Fax: 010 4391028
e-mail: hdc@erasmusmc.nl
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age minimal 18 years; 2. Expected minimal 2 platelet transfusion requirements; 3. Written informed consent; 4. Having a hemato-oncological disease
Exclusion criteria
Exclusion criteria: 1. Known immunological refractoriness to platelet transfusions, i.e. HLA- and/or HPA-allo immunization and/or clinical relevant auto-antibodies; 2. Pregnancy (or lactating); 3. Previous inclusion in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. 1 hour CCI | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. 24 hour CCI 2. Bleeding grade minimal 2 (CTCAE v3.0) 3. Transfusion requirement, red cells and platelets 4. Platelet transfusion interval 5. Adverse transfusion reactions | — |
Contacts
Public ContactJ.L.H. Kerkhoffs
HagaHospital, Leyweg 275
Outcome results
None listed